Bioventus (BVS) Income from Continuing Operations (2020 - 2026)
Bioventus (BVS) posted Income from Continuing Operations of 3946000.0 for Q1 2026, down 77.21% on a QoQ basis from 17318000.0 in Q4 2025, and up 218.78% year-over-year from 1237829.27 in Q1 2025.
Bioventus (BVS) Income from Continuing Operations (2020 - 2026) Analysis & Trends
Bioventus' Income from Continuing Operations history runs 7 years deep, the most recent figure standing at 3946000.0 for Q1 2026.
- Quarterly Income from Continuing Operations rose 218.78% year-over-year to 3946000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 34542000.0 (up 178.52% YoY) and the FY2025 annual result came in at 27274000.0, up 157.97% from the prior year.
- Income from Continuing Operations was 3946000.0 for Q1 2026 at Bioventus, down from 17318000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 17318000.0 in Q4 2025 and bottomed at 101035000.0 in Q4 2022.
- A 5-year average of 16569176.47 and a median of 6381000.0 in 2024 frame the typical range for Income from Continuing Operations.
- Annual changes were most pronounced in 2022 — Income from Continuing Operations slumped 85808.0% — and 2025, when it surged 2971.97%.
- Bioventus' Income from Continuing Operations stood at 21477000.0 in 2022, then surged by 64.35% to 7656000.0 in 2023, then soared by 92.12% to 603000.0 in 2024, then jumped by 2971.97% to 17318000.0 in 2025, then tumbled by 77.21% to 3946000.0 in 2026.
- Business Quant data shows BVS's Income from Continuing Operations at 3946000.0 in Q1 2026, 17318000.0 in Q4 2025, and 4006000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.06 Bn | 175.76 Bn | 6.27 Bn | 1.08 Bn |
| 2 | Stryker | 128.66 Bn | 125.78 Bn | 3.81 Bn | 745.00 Mn |
| 3 | Medtronic | 108.82 Bn | 99.60 Bn | 6.41 Bn | 1.26 Bn |
| 4 | Boston Scientific | 68.43 Bn | 66.98 Bn | 3.61 Bn | 1.34 Bn |
| 5 | Edwards Lifesciences | 48.29 Bn | 44.61 Bn | 1.29 Bn | 380.70 Mn |
| 6 | GE HealthCare Technologies | 28.37 Bn | 26.08 Bn | 1.98 Bn | 411.00 Mn |
| 7 | Dexcom | 28.29 Bn | 27.18 Bn | 750.30 Mn | 199.50 Mn |
| 8 | Smith & Nephew | 26.89 Bn | 26.31 Bn | - | - |
| 9 | Koninklijke Philips | 25.43 Bn | 22.31 Bn | 2.07 Bn | 273.95 Mn |
| 10 | Bioventus | 825.05 Mn | 789.21 Mn | 90.77 Mn | 3.95 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 28, 2026 | 3.95 Mn |
| Dec 31, 2025 | 17.32 Mn |
| Sep 27, 2025 | 4.01 Mn |
| Jun 28, 2025 | 9.27 Mn |
| Mar 29, 2025 | -3.32 Mn |
| Dec 31, 2024 | -603,000.00 |
| Sep 28, 2024 | -5.85 Mn |
| Jun 29, 2024 | -34.22 Mn |
| Mar 30, 2024 | -6.38 Mn |
| Dec 31, 2023 | -7.66 Mn |
| Sep 30, 2023 | -8.79 Mn |
| Jul 1, 2023 | -4.73 Mn |
| Apr 1, 2023 | -100.02 Mn |
| Dec 31, 2022 | -21.48 Mn |
| Oct 1, 2022 | -101.04 Mn |
| Jul 2, 2022 | -7.73 Mn |
| Apr 2, 2022 | -14.41 Mn |
| Dec 31, 2021 | -25,000.00 |
| Oct 2, 2021 | -2.27 Mn |
| Jul 3, 2021 | -10.78 Mn |